CARsgen Therapeutics completes enrollment in Phase II trial of Satri-cel for advanced gastric cancer
CARsgen Therapeutics Holdings Limited, a prominent player in the field of CAR T-cell therapies, has announced the successful completion of patient enrollment for its pivotal Phase II clinical trial of Satri-cel (satricabtagene autoleucel). This advanced autologous CAR T-cell product candidate targets Claudin18.2 and aims to treat patients with advanced gastric and gastroesophageal junction cancers (GC/GEJ) […]